Biotech RadarJobs updated

COMPANY

Emergent BioSolutions

HQ: Gaithersburg, MD source · emergentbiosolutions.com ↗ · Mid-Atlantic

Clinical Phase 3

Emergent BioSolutions is listed on ClinicalTrials.gov as the lead sponsor of 47 studies; the most recently updated is “CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma” (Phase 2, terminated), in T-cell Lymphoma. From public records Source · Oct 12, 2026

Keywords: Anthrax Bacterial Infections Smallpox T-cell Lymphoma Botulism Viral Infection Smallpox Vaccine Adverse Reaction Opioid Overdose Complication of Smallpox Vaccination Inhalational Anthrax COVID-19 SARS-CoV-2 Infection Cyanide Poisoning Human Influenza Typhoid Adenoviral Infection Influenza A H3N2 Influenza A H1N1 HIV Vaccine Myocarditis Pericarditis Bacillus Anthracis (Anthrax) Infection Anthrax Infection Bird Flu Influenza Zika Virus Infection Zika Virus Disease Symptoms of Inhalational Anthrax Pregnancy Complications Pregnancy Outcome Congenital Abnormalities AV7909 Collection of samples CYFENDUS

Location: Gaithersburg, MD · source · Sep 14, 2026

Profile checked Oct 10, 2026

47Trials (company is sponsor)

Timeline

  1. Trial start —: Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease. source ↗
  2. Trial start —: A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients source ↗
  3. Trial start —: Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax source ↗
  4. Trial start Phase 4: Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario source ↗
  5. Trial start —: Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax source ↗
  6. Debt Debt: $150M (not counted as a raise), announced Apr 16, 2026. Source: SEC filing. source ↗
  7. Debt Debt: $100M (not counted as a raise), announced Jan 12, 2026. Source: company release on GlobeNewswire. source ↗
  8. Grant Government contract: $16.7M (total, as published), announced Jan 13, 2025. Source: company release on GlobeNewswire. source ↗
  9. Trial start Phase 1: Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults source ↗
  10. Trial start Phase 1: Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults source ↗
  11. Trial start Phase 1: Study of SIAN Nasal Spray in Healthy Adults source ↗
  12. Trial start Phase 1: A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults source ↗
  13. Trial start Phase 1: Universal Influenza A Vaccine in Healthy Adults source ↗
  14. Trial start Phase 1: A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults source ↗
  15. Trial start Phase 2: Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study source ↗
  16. Trial start Phase 3: VELOCITY: An Anthrax Vaccine Clinical Study source ↗
  17. Trial start Phase 1: Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG) source ↗
  18. Trial start Phase 2: Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A source ↗
  19. Trial start Phase 1: A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 source ↗
  20. Trial start Phase 1: Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects source ↗
  21. Trial start Phase 4: VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV source ↗
  22. Trial start Phase 1: Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults source ↗
  23. Trial start Phase 4: Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed source ↗
  24. Trial start Phase 4: BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients source ↗
  25. Trial start —: BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin source ↗

Showing 25 of 50 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Debt: $250.0M. Last 2 years.

Clinical trials (lead sponsor) 47

RecordTitlePhaseStatusStartPrimary completion
NCT00893516CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaPhase 2Terminated2007-052008-10 (actual)
NCT05377255Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy AdultsPhase 1CompletedMar 28, 2022May 10, 2022 (actual)
NCT01374984VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia InfectionNot listedEnrolling by invitation2007-082027-08 (estimated)
NCT03877926VELOCITY: An Anthrax Vaccine Clinical StudyPhase 3CompletedMar 11, 2019Aug 6, 2020 (actual)
NCT07478471Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxNot listedNot yet recruiting2027-052030-05 (estimated)
NCT03569514Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNot listedNot yet recruitingNov 30, 20262027-07 (estimated)
NCT02177721Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioPhase 4Not yet recruiting2027-012035-05 (estimated)
NCT03569553A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNot listedNot yet recruitingMay 30, 20272027-07 (estimated)
NCT02051062BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric PatientsPhase 4Enrolling by invitation2014-10Jul 31, 2028 (estimated)
NCT07268612Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.Not listedNot yet recruiting2035-112036-11 (estimated)
NCT04067011Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyPhase 2CompletedAug 12, 2019Mar 5, 2020 (actual)
NCT01753115Ciprofloxacin BioThrax Co-Administration StudyPhase 2Completed2012-122013-08 (actual)
NCT04661839A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy AdultsPhase 1CompletedDec 24, 2020Jul 27, 2021 (actual)
NCT05142306A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected AdultsPhase 1CompletedDec 7, 2021Mar 28, 2022 (actual)
NCT05194358Study of SIAN Nasal Spray in Healthy AdultsPhase 1CompletedDec 21, 2021Sep 29, 2023 (actual)
NCT05155319Universal Influenza A Vaccine in Healthy AdultsPhase 1CompletedDec 1, 2021Oct 10, 2023 (actual)
NCT05935917Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsPhase 1CompletedMay 30, 2023Aug 14, 2023 (actual)
NCT01491607Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsPhase 3Completed2011-112012-05 (actual)
NCT00679172Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsPhase 2Completed2008-052008-12 (actual)
NCT00928577Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)Not listedCompleted2008-122014-12 (actual)
NCT03160339A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047Phase 1TerminatedMay 1, 2017Nov 27, 2017 (actual)
NCT00053495Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationPhase 2Completed2003-012003-06 (actual)
NCT02061358Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy SubjectsPhase 1Completed2014-072015-07 (actual)
NCT02339155Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedPhase 4CompletedFeb 24, 2015Jan 3, 2017 (actual)
NCT01158157VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVPhase 3CompletedSep 13, 2010Feb 14, 2012 (actual)
NCT01311674Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)Phase 3Terminated2009-09Mar 11, 2011 (actual)
NCT03315104Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza APhase 2CompletedNov 17, 2017Jun 17, 2019 (actual)
NCT01540929Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military PersonnelNot listedCompleted2009-092012-09 (actual)
NCT02771730Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected AdultsPhase 1Terminated2015-032017-02 (actual)
NCT00877656HuMax-CD4 in Non-Cutaneous T-Cell LymphomaPhase 2/Phase 3Completed2005-082006-01 (actual)
NCT02443623VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIVPhase 4Completed2015-092021-07 (actual)
NCT01395082ACAM2000® Myopericarditis RegistryNot listedCompleted2011-04Feb 4, 2019 (actual)
NCT00636519Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB MusclePhase 1Completed2008-022009-10 (actual)
NCT01263691Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsPhase 1Completed2010-122012-05 (actual)
NCT02696291Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy SubjectsPhase 1TerminatedMay 27, 2016Mar 2, 2017 (actual)
NCT01979406A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines1Completed2013-112014-10 (actual)
NCT00927719Safety Surveillance Study of ACAM2000® Vaccinia VaccineNot listedCompleted2008-12Dec 31, 2017 (actual)
NCT00053482Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsPhase 2Completed2003-012003-04 (actual)
NCT00360737Safety Study of 7 Botulinum Antitoxin Serotypes Derived From HorsesPhase 1Completed2006-072006-12 (actual)
NCT01770743A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels2Completed2013-012014-02 (actual)
NCT01006798Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1Phase 1Completed2009-102011-09 (actual)
NCT03624946Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)Phase 1CompletedJun 27, 2018Mar 6, 2019 (actual)
NCT00845650Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)Phase 1/Phase 2Completed2009-022010-10 (actual)
NCT00448253Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human SerumPhase 1Completed2007-072008-08 (actual)
NCT01653392BioThrax® (Anthrax) Vaccine in Pregnancy RegistryNot listedCompleted2012-072020-02 (actual)
NCT02055183BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum AntitoxinNot listedCompleted2014-102017-07 (actual)
NCT01202695Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)Phase 1Completed2010-082011-06 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback